Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription

Articles published in Br J Cancer

Retrieve available abstracts of 66 articles:
HTML format

Single Articles

    June 2022
  1. MASUKUME G, Mmbaga BT, Dzamalala CP, Mlombe YB, et al
    A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case-control studies.
    Br J Cancer. 2022 Jun 29. pii: 10.1038/s41416-022-01890.
    PubMed     Abstract available

  2. MAKINO T, Yamasaki M, Tanaka K, Yamashita K, et al
    Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma.
    Br J Cancer. 2022;126:1555-1562.
    PubMed     Abstract available

  3. ALMANGUSH A, Jouhi L, Atula T, Haglund C, et al
    Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group.
    Br J Cancer. 2022;126:1589-1594.
    PubMed     Abstract available

    March 2022
  4. BOLGER JC, Donohoe CL, Lowery M, Reynolds JV, et al
    Advances in the curative management of oesophageal cancer.
    Br J Cancer. 2022;126:706-717.
    PubMed     Abstract available

  5. ANDREW TW, Hamnett N, Roy I, Garioch J, et al
    Machine-learning algorithm to predict multidisciplinary team treatment recommendations in the management of basal cell carcinoma.
    Br J Cancer. 2022;126:562-568.
    PubMed     Abstract available

    February 2022
  6. PATEL U, Kannan S, Rane SU, Mittal N, et al
    Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab.
    Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-022-01730.
    PubMed     Abstract available

  7. FLACH S, Howarth K, Hackinger S, Pipinikas C, et al
    Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
    Br J Cancer. 2022 Feb 7. pii: 10.1038/s41416-022-01716.
    PubMed     Abstract available

    January 2022
  8. SCHACK LMH, Naderi E, Fachal L, Dorling L, et al
    A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis.
    Br J Cancer. 2022 Jan 17. pii: 10.1038/s41416-021-01670.
    PubMed     Abstract available

    December 2021
  9. HUTCHISON IL, Ridout F, Cheung SMY, Shah N, et al
    Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.
    Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01678.

  10. WEI Y, Wu W, Jiang Y, Zhou H, et al
    Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01651.
    PubMed     Abstract available

  11. MISHRA V, Singh A, Chen X, Rosenberg AJ, et al
    Application of liquid biopsy as multi-functional biomarkers in head and neck cancer.
    Br J Cancer. 2021 Dec 7. pii: 10.1038/s41416-021-01626.
    PubMed     Abstract available

    November 2021
  12. KOBAYASHI T, Makino T, Yamashita K, Saito T, et al
    APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation.
    Br J Cancer. 2021;125:1523-1532.
    PubMed     Abstract available

    October 2021
  13. XIE SH, Santoni G, Lagergren J
    Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01575.
    PubMed     Abstract available

  14. THEODORAKI MN, Laban S, Jackson EK, Lotfi R, et al
    Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients.
    Br J Cancer. 2021 Oct 12. pii: 10.1038/s41416-021-01567.
    PubMed     Abstract available

  15. BOUROVA-FLIN E, Derakhshan S, Goudarzi A, Wang T, et al
    The combined detection of Amphiregulin, Cyclin A1 and DDX20/Gemin3 expression predicts aggressive forms of oral squamous cell carcinoma.
    Br J Cancer. 2021;125:1122-1134.
    PubMed     Abstract available

  16. BAXTER MA, Middleton F, Cagney HP, Petty RD, et al
    Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers.
    Br J Cancer. 2021;125:1068-1079.
    PubMed     Abstract available

  17. DE PAULA B, C Smyth E
    Personalising care in oesophageal cancer care with liquid biopsy.
    Br J Cancer. 2021;125:1036-1038.
    PubMed     Abstract available

    September 2021
  18. ZOU Z, Zheng W, Fan H, Deng G, et al
    Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells.
    Br J Cancer. 2021;125:826-838.
    PubMed     Abstract available

    August 2021
  19. LIANG J, Jin Z, Kuang J, Feng H, et al
    The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
    Br J Cancer. 2021;125:390-401.
    PubMed     Abstract available

  20. GAO S, Liu Y, Duan X, Liu K, et al
    Porphyromonas gingivalis infection exacerbates oesophageal cancer and promotes resistance to neoadjuvant chemotherapy.
    Br J Cancer. 2021;125:433-444.
    PubMed     Abstract available

  21. SATHASIVAM HP, Kist R, Sloan P, Thomson P, et al
    Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology.
    Br J Cancer. 2021;125:413-421.
    PubMed     Abstract available

  22. YUAN Y, Zhao Z, Xue L, Wang G, et al
    Identification of diagnostic markers and lipid dysregulation in oesophageal squamous cell carcinoma through lipidomic analysis and machine learning.
    Br J Cancer. 2021;125:351-357.
    PubMed     Abstract available

  23. DAVERN M, Donlon NE, Power R, Hayes C, et al
    The tumour immune microenvironment in oesophageal cancer.
    Br J Cancer. 2021;125:479-494.
    PubMed     Abstract available

    July 2021
  24. WU P, Xie C, Yang L, Liu Y, et al
    The genomic architectures of tumour-adjacent tissues, plasma and saliva reveal evolutionary underpinnings of relapse in head and neck squamous cell carcinoma.
    Br J Cancer. 2021 Jul 6. pii: 10.1038/s41416-021-01464.
    PubMed     Abstract available

    June 2021
  25. SULKSHANE P, Pawar SN, Waghole R, Pawar SS, et al
    Elevated USP9X drives early-to-late-stage oral tumorigenesis via stabilisation of anti-apoptotic MCL-1 protein and impacts outcome in oral cancers.
    Br J Cancer. 2021 Jun 2. pii: 10.1038/s41416-021-01421.
    PubMed     Abstract available

  26. ZOLGHADR F, Tse N, Loka D, Joun G, et al
    A Wnt-mediated phenotype switch along the epithelial-mesenchymal axis defines resistance and invasion downstream of ionising radiation in oral squamous cell carcinoma.
    Br J Cancer. 2021;124:1921-1933.
    PubMed     Abstract available

  27. SHRIWAS O, Arya R, Mohanty S, Mohapatra P, et al
    RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway.
    Br J Cancer. 2021;124:2004-2016.
    PubMed     Abstract available

    May 2021
  28. JENSEN KH, Vogelius I, Moser CE, Andersen E, et al
    Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database.
    Br J Cancer. 2021 May 20. pii: 10.1038/s41416-021-01430.
    PubMed     Abstract available

  29. KNIGHT WRC, Baker CR, Griffin N, Wulaningsih W, et al
    Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?
    Br J Cancer. 2021;124:1653-1660.
    PubMed     Abstract available

    April 2021
  30. MAHMOOD H, Shaban M, Rajpoot N, Khurram SA, et al
    Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview.
    Br J Cancer. 2021 Apr 19. pii: 10.1038/s41416-021-01386.
    PubMed     Abstract available

    March 2021
  31. CHEN Y, Maniakas A, Tan L, Cui M, et al
    Development of a rational strategy for integration of lactate dehydrogenase A suppression into therapeutic algorithms for head and neck cancer.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01297.
    PubMed     Abstract available

  32. OLIVA M, Schneeberger PHH, Rey V, Cho M, et al
    Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).
    Br J Cancer. 2021 Mar 10. pii: 10.1038/s41416-020-01253.
    PubMed     Abstract available

  33. LIU Y, Baba Y, Ishimoto T, Tsutsuki H, et al
    Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma.
    Br J Cancer. 2021;124:963-974.
    PubMed     Abstract available

    February 2021
  34. NG SP, Bahig H, Jethanandani A, Sturgis EM, et al
    Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy.
    Br J Cancer. 2021;124:628-633.
    PubMed     Abstract available

  35. KILLCOYNE S, Fitzgerald RC
    Practical early cancer detection: distinguishing stable from unstable genomes in pre-cancerous tissues.
    Br J Cancer. 2021;124:683-685.
    PubMed     Abstract available

    December 2020
  36. KIM HR, Kang HN, Yun MR, Ju KY, et al
    Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
    Br J Cancer. 2020;123:1720-1729.
    PubMed     Abstract available

  37. PATEL U, Pandey M, Kannan S, Samant TA, et al
    Prognostic and predictive significance of nuclear HIF1alpha expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
    Br J Cancer. 2020;123:1757-1766.
    PubMed     Abstract available

    November 2020
  38. BAXTER MA, Spender LC, Petty RD
    Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma.
    Br J Cancer. 2020;123:1585-1587.
    PubMed     Abstract available

  39. XIE C, Jing Z, Luo H, Jiang W, et al
    Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.
    Br J Cancer. 2020;123:1616-1624.
    PubMed     Abstract available

    October 2020
  40. OPENSHAW MR, Mohamed AA, Ottolini B, Fernandez-Garcia D, et al
    Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma.
    Br J Cancer. 2020;123:1271-1279.
    PubMed     Abstract available

  41. WANG Y, Li Q, Niu L, Xu L, et al
    Suppression of G6PD induces the expression and bisecting GlcNAc-branched N-glycosylation of E-Cadherin to block epithelial-mesenchymal transition and lymphatic metastasis.
    Br J Cancer. 2020;123:1315-1325.
    PubMed     Abstract available

  42. CAPONIO VCA, Troiano G, Adipietro I, Zhurakivska K, et al
    Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer.
    Br J Cancer. 2020;123:1302-1314.
    PubMed     Abstract available

    September 2020
  43. DHARMAWARDANA N, Goddard T, Woods C, Watson DI, et al
    Development of a non-invasive exhaled breath test for the diagnosis of head and neck cancer.
    Br J Cancer. 2020 Sep 9. pii: 10.1038/s41416-020-01051.
    PubMed     Abstract available

    August 2020
  44. DI CREDICO G, Polesel J, Dal Maso L, Pauli F, et al
    Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration.
    Br J Cancer. 2020 Aug 24. pii: 10.1038/s41416-020-01031.
    PubMed     Abstract available

  45. ELKASHTY OA, Tran SD
    Broccoli extract increases drug-mediated cytotoxicity towards cancer stem cells of head and neck squamous cell carcinoma.
    Br J Cancer. 2020 Aug 10. pii: 10.1038/s41416-020-1025.
    PubMed     Abstract available

  46. YAMAMOTO T, Hirosue A, Nakamoto M, Yoshida R, et al
    BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene.
    Br J Cancer. 2020;123:580-590.
    PubMed     Abstract available

    July 2020
  47. HUTCHISON I, Hackshaw A
    Reply to Comment(s) on "Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort".
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0983.

  48. DHAR H, Vaish R, D'Cruz AK
    Comment on "Nationwide randomised trial evaluating elective neck dissection for early-stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort."
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0981.

  49. SINGH A, Subash A, Sinha P
    Comment on "Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort".
    Br J Cancer. 2020 Jul 16. pii: 10.1038/s41416-020-0982.

  50. WAGNER S, Prigge ES, Wuerdemann N, Reder H, et al
    Evaluation of p16(INK4a) expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation.
    Br J Cancer. 2020 Jul 6. pii: 10.1038/s41416-020-0964.
    PubMed     Abstract available

  51. XU K, Fu Y, Han Y, Xia R, et al
    Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk "Infiltrating" HPV(-) HNSCC.
    Br J Cancer. 2020 Jul 3. pii: 10.1038/s41416-020-0966.
    PubMed     Abstract available

  52. RONG C, Muller MF, Xiang F, Jensen A, et al
    Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC.
    Br J Cancer. 2020;123:288-297.
    PubMed     Abstract available

  53. CHEN X, Zhuo S, Xu W, Chen X, et al
    Isocitrate dehydrogenase 2 contributes to radiation resistance of oesophageal squamous cell carcinoma via regulating mitochondrial function and ROS/pAKT signalling.
    Br J Cancer. 2020;123:126-136.
    PubMed     Abstract available

  54. KAGOHARA LT, Zamuner F, Davis-Marcisak EF, Sharma G, et al
    Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines.
    Br J Cancer. 2020;123:101-113.
    PubMed     Abstract available

    June 2020
  55. MORVAN VL, Richard E, Cadars M, Fessart D, et al
    Cytochrome P450 1B1 polymorphism drives cancer cell stemness and patient outcome in head-and-neck carcinoma.
    Br J Cancer. 2020 Jun 22. pii: 10.1038/s41416-020-0932.
    PubMed     Abstract available

  56. BAYSAL H, De Pauw I, Zaryouh H, De Waele J, et al
    Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
    Br J Cancer. 2020 Jun 16. pii: 10.1038/s41416-020-0934.
    PubMed     Abstract available

  57. SHAH SC, Dai Q, Zhu X, Peek RM Jr, et al
    Associations between calcium and magnesium intake and the risk of incident oesophageal cancer: an analysis of the NIH-AARP Diet and Health Study prospective cohort.
    Br J Cancer. 2020;122:1857-1864.
    PubMed     Abstract available

    May 2020
  58. KIM JH, Han KD, Lee JK, Kim HS, et al
    Association between the National Cancer Screening Programme (NSCP) for gastric cancer and oesophageal cancer mortality.
    Br J Cancer. 2020 May 13. pii: 10.1038/s41416-020-0883.
    PubMed     Abstract available

  59. RASMUSSEN JH, Olin A, Lelkaitis G, Hansen AE, et al
    Does multiparametric imaging with (18)F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0876.
    PubMed     Abstract available

  60. KO JM, Vardhanabhuti V, Ng WT, Lam KO, et al
    Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma.
    Br J Cancer. 2020 May 6. pii: 10.1038/s41416-020-0871.
    PubMed     Abstract available

  61. OKADOME K, Baba Y, Nomoto D, Yagi T, et al
    Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
    Br J Cancer. 2020;122:1535-1543.
    PubMed     Abstract available

  62. TOGO M, Yokobori T, Shimizu K, Handa T, et al
    Diagnostic value of (18)F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8(+)tumour-infiltrating lymphocytes in oral squamous cell carcinoma.
    Br J Cancer. 2020;122:1686-1694.
    PubMed     Abstract available

  63. KIM MH, Kim JH, Lee JM, Choi JW, et al
    Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response.
    Br J Cancer. 2020;122:1649-1660.
    PubMed     Abstract available

    February 2020
  64. PORTER RJ, Murray GI, Brice DP, Petty RD, et al
    Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression-epithelial HMGB1 expression and stromal lymphocytic phenotype.
    Br J Cancer. 2020;122:545-554.
    PubMed     Abstract available

  65. TSAKIROGLOU AM, Fergie M, Oguejiofor K, Linton K, et al
    Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma.
    Br J Cancer. 2020;122:539-544.
    PubMed     Abstract available

  66. HATOGAI K, Fujii S, Kitano S, Kojima T, et al
    Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma.
    Br J Cancer. 2020;122:413-420.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.